These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 19169493)
61. [From gene to disease; neonatal diabetes mellitus and the KCNJ11 gene]. Slingerland AS; Bruining GJ Ned Tijdschr Geneeskd; 2005 Dec; 149(49):2732-6. PubMed ID: 16375017 [TBL] [Abstract][Full Text] [Related]
62. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation. Philla KQ; Bauer AJ; Vogt KS; Greeley SA Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373 [No Abstract] [Full Text] [Related]
63. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report. Heo JW; Kim SW; Cho EH Diabetes Res Clin Pract; 2013 Apr; 100(1):e1-2. PubMed ID: 23434183 [TBL] [Abstract][Full Text] [Related]
64. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Sagen JV; Raeder H; Hathout E; Shehadeh N; Gudmundsson K; Baevre H; Abuelo D; Phornphutkul C; Molnes J; Bell GI; Gloyn AL; Hattersley AT; Molven A; Søvik O; Njølstad PR Diabetes; 2004 Oct; 53(10):2713-8. PubMed ID: 15448106 [TBL] [Abstract][Full Text] [Related]
65. Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China. Li X; Xu A; Sheng H; Ting TH; Mao X; Huang X; Jiang M; Cheng J; Liu L Pediatr Diabetes; 2018 Mar; 19(2):251-258. PubMed ID: 28791793 [TBL] [Abstract][Full Text] [Related]
66. Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus. Ting WH; Huang CY; Lo FS; Lee HC; Lin CL; Guo WL; Lee YJ J Pediatr Endocrinol Metab; 2009 Jul; 22(7):661-7. PubMed ID: 19774848 [TBL] [Abstract][Full Text] [Related]
67. Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation. Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D Diabet Med; 2020 Nov; 37(11):1956-1958. PubMed ID: 32634858 [No Abstract] [Full Text] [Related]
68. Diabetes caused by Kir6.2 mutation: successful treatment with oral glibenclamide switched from continuous subcutaneous insulin infusion in the early phase of the disease. Nagano N; Urakami T; Mine Y; Watanabe H; Yoshida A; Suzuki J; Saito H; Ishige M; Takahashi S; Mugishima H; Yorifuji T Pediatr Int; 2012 Apr; 54(2):277-9. PubMed ID: 22507152 [No Abstract] [Full Text] [Related]
69. Sulfonylurea-responsive diabetes in childhood. Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235 [TBL] [Abstract][Full Text] [Related]
70. Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations. Letourneau LR; Greeley SAW Curr Diab Rep; 2019 Jun; 19(8):52. PubMed ID: 31250216 [TBL] [Abstract][Full Text] [Related]
71. Glibenclamide for neonatal diabetes. Kochar IP; Jindal R Indian Pediatr; 2013 Apr; 50(4):428-9. PubMed ID: 23665609 [No Abstract] [Full Text] [Related]
72. Clinical features and partial proportional molecular genetics in neonatal diabetes mellitus: a retrospective analysis in southwestern China. Cao L; He Y; Huang Q; Zhang Y; Deng P; Du W; Hua Z; Zhu M; Wei H Endocrine; 2020 Jul; 69(1):53-62. PubMed ID: 32279225 [TBL] [Abstract][Full Text] [Related]
73. The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy. Klupa T; Kozek E; Nowak N; Cyganek K; Gach A; Milewicz T; Czajkowski K; Tolloczko J; Mlynarski W; Malecki MT J Clin Endocrinol Metab; 2010 Aug; 95(8):3599-604. PubMed ID: 20466780 [TBL] [Abstract][Full Text] [Related]
74. The first clinical case of a mutation at residue K185 of Kir6.2 (KCNJ11): a major ATP-binding residue. Shimomura K; de Nanclares GP; Foutinou C; Caimari M; Castaño L; Ashcroft FM Diabet Med; 2010 Feb; 27(2):225-9. PubMed ID: 20546268 [TBL] [Abstract][Full Text] [Related]
75. Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion. Fendler W; Pietrzak I; Brereton MF; Lahmann C; Gadzicki M; Bienkiewicz M; Drozdz I; Borowiec M; Malecki MT; Ashcroft FM; Mlynarski WM Diabetes Care; 2013 Aug; 36(8):2311-6. PubMed ID: 23462667 [TBL] [Abstract][Full Text] [Related]